医药政策法规
- (2023-03-14)
- (2023-03-14)
- (2023-03-14)
- (2023-03-13)
- (2023-03-13)
- (2023-03-13)
- (2023-03-13)
- (2023-03-13)
- (2023-03-13)
- (2023-03-13)
- (2023-03-10)
- (2023-03-10)
- (2023-03-10)
JCO:一次低剂量CT即可预测未来6年肺癌风险!MIT和哈佛研究团队开发的AI模型可不依赖放射科医生和临床数据,高准确率预测肺癌
(2023-03-10)- (2023-03-10)
- (2023-03-10)
- (2023-03-10)
- (2023-03-10)
- (2023-03-10)
- (2023-03-09)
- (2023-03-09)
- (2023-03-09)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-08)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-07)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-06)
- (2023-03-05)
PROpel III 期关键结果:与阿比特龙单药相比,奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌中位总生存期的绝对差异增加了7.4个月
(2023-03-05)- (2023-03-05)
- (2023-03-05)